Corcept Therapeutics Incorporated (NASDAQ: CORT) presented overall survival data from its Phase 3 ROSELLA trial of Lifyorli (relacorilant) plus nab-paclitaxel at the ASCO 2026 Annual Meeting. The data showed patients treated with the combination experienced a 35% reduction in the risk of death compared to patients treated with nab-paclitaxel alone.

In the trial, patients receiving Lifyorli combined with nab-paclitaxel had a median overall survival of 16.0 months, compared to 11.9 months for patients receiving nab-paclitaxel alone. The hazard ratio was 0.65 with a p-value of 0.0004.

The survival benefits were observed across all prespecified subgroups in the trial. Patients with a taxane-free interval of 6 months or less showed a hazard ratio of 0.60, while those who received a taxane in their most recent treatment regimen had a hazard ratio of 0.67.

The ROSELLA trial enrolled 381 patients with platinum-resistant ovarian cancer at sites in the United States, Europe, South Korea, Brazil, Argentina, Canada and Australia. Patients were randomized 1:1 to receive either relacorilant plus nab-paclitaxel or nab-paclitaxel alone.

Lifyorli, in combination with nab-paclitaxel, received FDA approval in March 2026 for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. The drug is the first FDA-approved selective glucocorticoid receptor antagonist.

The combination was well-tolerated in the trial, with adverse events comparable to those in the nab-paclitaxel monotherapy arm. The most common adverse reactions experienced by more than 20% of patients included decreased hemoglobin, decreased neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash, and decreased appetite.